Advanced Filters
noise

San Francisco, California Clinical Trials

A listing of San Francisco, California clinical trials actively recruiting patient volunteers.

Found 683 clinical trials
M Mehrdad Arjomandi, MD

Secondhand Tobacco Smoke and Cardiovascular Disease

This is a double-blind randomized placebo-controlled crossover clinical trial of efficacy and safety of an FDA-approved angiotensin receptor blocker (losartan) to improve cardiopulmonary outcomes in individuals with pre-Chronic Obstructive Pulmonary Disease (COPD) due to prolonged exposure to secondhand tobacco smoke.

40 years of age All Phase 4
D Dominique Lafreniere

Neuroblastoma Maintenance Therapy Trial

Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 ± 250 mg/m2 BID (strata 1, 2, 3, and 4) OR 2500 mg/m2 …

1 - 30 years of age All Phase 2
J Jennifer Miller

DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma

Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma.

- 21 years of age All Phase 2
M Mark Hall

Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS

The TRIPS study is a prospective, multi-center, double-blind, adaptively randomized, placebo-controlled clinical trial of the drug anakinra for reversal of moderate to severe hyperinflammation in children with sepsis-induced multiple organ dysfunction syndrome (MODS).

1 - 17 years of age All Phase 2/3

Safety & PK of MBRC-101 in Advanced Refractory Solid Tumors

This is a first-in-human (FIH), open label Phase 1/1b study in patients with advanced metastatic solid tumors refractory to standard treatment. Phase 1 will identify potential optimal biologically relevant doses (OBRD) and the maximum tolerated dose (MTD) of MBRC-101 at one 1 or more dosing regimens. Phase 1b will evaluate …

18 years of age All Phase 1

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

This study is for older children, adolescents, and young adults with B-cell Acute Lymphoblastic Leukemia (B-ALL). Higher amounts of body fat is associated with resistance to chemotherapy in patients with B-ALL. Chemotherapy during the first month causes large gains in body fat in most people, even those who start chemotherapy …

10 - 25 years of age All Phase 2
L Laura Koth, MD

Use of CXCL9 as a Biomarker of Acthar Efficacy

The objective is this study is to test whether use of Acthar gel in the context of sarcoidosis will lead to improved symptoms and lung function and correlate with decreased levels of predictive blood biomarkers, like chemokine ligand 9 (CXCL9).

18 - 65 years of age All Phase 4
S Sara Onesi, RN

Metformin for Pulmonary Hypertension HFpEF

The main objective of this study is to determine the clinical efficacy of metformin versus placebo and the therapeutic response with regards to functional capacity and hemodynamics in PH-HFpEF.

18 years of age All Phase 2
M Megan McLaughlin, MD, MPH

Text Education About Cardiovascular Health and HIV (TEACH-HIV)

The overall objective is to evaluate the efficacy of educational text messages to reduce cardiovascular risk among persons living with HIV (PLWH).

40 years of age All Phase N/A
Y Yingxin Jia, PhD

Medial-prefrontal Enhancement During Schizophrenia Systems Imaging

This randomized controlled trial in healthy controls (HC) and patients with schizophrenia (SZ) aims to examine 1) the underlying cognitive and neural cause of self-agency deficits in SZ; 2) the responsiveness to a novel navigated repetitive transcranial magnetic stimulation (nrTMS) target in the medial/superior prefrontal cortex (mPFC); and 3) how …

18 - 64 years of age All Phase N/A

Simplify language using AI